Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]

Molecular medicine in lung cancer

Dr Reinhard Büttner - University Hospital of Cologne, Cologne, Germany

Molecular medicine in lung cancer ( Dr Reinhard Büttner - University Hospital of Cologne, Cologne, Germany )

Improving care for cancer patients

Dr David Hui - MD Anderson Cancer Center, Houston, USA

Improving care for cancer patients ( Dr David Hui - MD Anderson Cancer Center, Houston, USA )

Managing cancer and living meaningfully

Dr Gary M. Rodin - UHN Princess Margaret Hospital, Toronto, Canada

Managing cancer and living meaningfully ( Dr Gary M. Rodin - UHN Princess Margaret Hospital, Toronto, Canada )

Dacomitinib for EGFR positive lung cancer

Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China

Dacomitinib for EGFR positive lung cancer ( Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China )

New ALK inhibitor alectinib halts lung cancer growth more than a year longer...

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers ( Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA )

Immunotherapy may slow the growth of malignant pleural mesothelioma

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy may slow the growth of malignant pleural mesothelioma ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

Immunotherapy for mesothelioma could be on the horizon

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy for mesothelioma could be on the horizon ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

Alectinib eclipses crizotinib for ALK positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Alectinib eclipses crizotinib for ALK positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

New personalised therapies for lung cancer

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

New personalised therapies for lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain

Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )

Nivolumab for NSCLC: five years on

Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA

Nivolumab for NSCLC: five years on ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

More from ecancer